HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Paul Chaplin Selected Research

Vaccinia

9/2015Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.
4/2015Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.
1/2015A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.
1/2015Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study population.
9/2014Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis.
5/2014Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.
6/2013Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.
3/2013Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.
9/2010A major role for TLR8 in the recognition of vaccinia viral DNA by murine pDC?
2/2010A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Paul Chaplin Research Topics

Disease

16Vaccinia
09/2015 - 03/2003
8Smallpox (Variola)
04/2015 - 03/2006
3Neoplasms (Cancer)
01/2013 - 08/2004
3Melanoma (Melanoma, Malignant)
05/2005 - 09/2003
2Atopic Dermatitis (Atopic Eczema)
01/2015 - 09/2014
2Communicable Diseases (Infectious Diseases)
01/2013 - 05/2006
1Infection
12/2014
1Kaposi Varicelliform Eruption (Eczema Herpeticum)
09/2014
1Cowpox
05/2006
1Human Influenza (Influenza)
03/2003

Drug/Important Bio-Agent (IBA)

8VaccinesIBA
04/2015 - 03/2006
7Smallpox VaccineFDA Link
09/2015 - 02/2010
4imvamuneIBA
01/2015 - 12/2007
3Monophenol Monooxygenase (Tyrosinase)IBA
05/2005 - 09/2003
2AntigensIBA
05/2005 - 08/2004
1AntibodiesIBA
01/2015
1Double-Stranded RNA (RNA, Double Stranded)IBA
12/2014
1Proteins (Proteins, Gene)IBA
12/2014
1Interferon Type IIBA
12/2014
1Protein Kinases (Protein Kinase)IBA
12/2014
1Neutralizing AntibodiesIBA
05/2014
1Biological Markers (Surrogate Marker)IBA
03/2013
1Viral DNAIBA
09/2010
1Complex MixturesIBA
12/2009
1Intergenic DNA (Junk DNA)IBA
05/2006
1Synthetic Vaccines (Recombinant Vaccines)IBA
05/2006
1DNA (Deoxyribonucleic Acid)IBA
03/2003

Therapy/Procedure

1Subcutaneous Injections
01/2015
1Immunotherapy
08/2004